Gounant V, Greillier L, Mascaux C, Pinquie F, Carmier D, Moreau L, Roch B, Debieuvre D, Dhalluin X, Giroux-Leprieur E, Berton E, Rabeau A, Raimbourg J, Dixmier A, Naltet C, Khalil A, Ezzeddine L, El Hajjam M, Langlais A, Morin F, Westeel V, Zalcman G, Duruisseaux M

JTO Clin Res Rep. 2025 12;6(12):100908

Detecting Airway Involvement in Non-Asthmatic Eosinophilic Disorders: Diagnostic Utility of Fractional Exhaled Nitric Oxide (FeNO).

Raoul N, Laurent L, Ritter O, Roux-Claudé P, Al Freijat F, Magy-Bertrand N, Westeel V, Barnig C

Adv Respir Med. 2025 09 16;93(5):

Distinctive Computed Tomography Features of Chronic Obstructive Pulmonary Disease Among Dairy Farmers and Smokers.

Mourouvin-Chevolot E, Laurent L, Claudé F, Westeel V, Calame P, Delabrousse E, Barnig C, Behr J

Respir Med. 2025 08 25;:108319

Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.

Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ,

Lancet Respir Med. 2025 06 24;:

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Gobbini E, Langlais A, Missy P, Chanoine S, Besse B, Souquet PJ, Barlesi F, Audigier-Valette C, Métivier AC, Monnet I, Hureaux J, Jeannin G, Cadranel J, Lagrange A, Tran Q, Morin F, Molinier O, Westeel V, Girard N, Moro-Sibilot D

Eur J Cancer. 2025 06 11;225:115560

Perioperative immunotherapy strategies for resectable non-small cell lung cancer.

Marchal C, Eberst G, Calais F, Westeel V, Malouf R

Cochrane Database Syst Rev. 2025 05 19;5(5):CD015819

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.

Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V

Eur J Cancer. 2025 02 11;219:115301

Prognostic value of blood eosinophils for predicting survival and treatment outcomes in people with non-small cell lung cancer.

Sultana H, De Vos T, Malouf R, Calais F, Marchal C, Eberst G, Westeel V, Barnig C

Cochrane Database Syst Rev. 2025 02 7;2(2):CD015783

Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.

Girard N, Guisier F, Swalduz A, Van Hulst S, Pichon E, Lavaud P, Greillier L, Tiotiu A, Madroszyk A, Bylicki O, Canellas A, Belmont L, Zysman M, Hauss PA, Godbert B, Audigier-Valette C, Lebreton C, Morin F, Westeel V

ESMO Open. 2024 11 27;9(12):103968

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.

Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB

Lung Cancer. 2024 11 26;199:108038

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB

Lung Cancer. 2024 08 24;196:107934

Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.

Orillard E, Adhikari A, Malouf RS, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2024 08 13;8(8):CD015495

Overall prognosis of index lung cancer recurrence or of second primary lung cancer in people with non-small cell lung cancer operated with complete resection.

Laforge L, Eberst G, Calais F, Malouf RS, Marchal C, Westeel V, Roqué-Figuls M

Cochrane Database Syst Rev. 2024 08 1;8(8):CD015319

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol.

Marchal C, Orillard E, Calais F, Westeel V

Cochrane Database Syst Rev. 2024 07 3;7(7):CD014907

Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.

Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, Leleu O, Amrane K, Berndt C, Langlais A, Morin F, Westeel V

Respir Med Res. 2024 04 30;86:101113

High risk of lung cancer in surfactant-related gene variant carriers.

Brudon A, Legendre M, Mageau A, Bermudez J, Bonniaud P, Bouvry D, Cadranel J, Cazes A, Crestani B, Dégot T, Delestrain C, Diesler R, Epaud R, Philippot Q, Theou-Anton N, Kannengiesser C, Ba I, Debray MP, Fanen P, Manali E, Papiris S, Nathan N, Amselem S, Gondouin A, Guillaumot A, Andréjak C, Jouneau S, Beltramo G, Uzunhan Y, Galodé F, Westeel V, Mehdaoui A, Hirschi S, Leroy S, Marchand-Adam S, Nunes H, Picard C, Prevot G, Reynaud-Gaubert M, De Vuyst P, Wemeau L, Defossez G, Zalcman G, Cottin V, Borie R,

Eur Respir J. 2024 04 4;:

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.

Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L

Lancet. 2023 11 3;:

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.

Westeel V, Schuette W, Urban T, Radonjic D, von Wangenheim U, Lorence RM, Reck M

PLoS One. 2023 10 17;18(10):e0292307

Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.

Reck M, Barlesi F, Chih-Hsin Yang J, Westeel V, Felip E, Özgüroğlu M, Cobo Dols M, Sullivan R, Kowalski DM, Andric Z, Ho Lee D, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Tadjalli Mehr K, Park K

J Thorac Oncol. 2023 09 23;:

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, Merle P, Lamy R, Madroszyk A, Otto J, Tomasini P, Assoun S, Canellas A, Gervais R, Hureaux J, Le Treut J, Leleu O, Naltet C, Tiercin M, Van Hulst S, Missy P, Morin F, Westeel V, Girard N

Lung Cancer. 2023 09 22;185:107379

Score to Predict the Occurrence of Pneumothorax After Computed Tomography-guided Percutaneous Transthoracic Lung Biopsy.

Lamfichekh Y, Lafay V, Hamam J, Guillien A, Puyraveau M, Behr J, Manzoni P, Calame P, Dalphin JC, Eberst G, Grillet F, Westeel V

J Thorac Imaging. 2023 09 1;38(5):315-324

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R

Mol Cancer. 2023 07 29;22(1):120

[The role of the cardiopulmonary exercise test and pulmonary rehabilitation in long COVID-19].

Noureddine S, Roux-Claudé P, Eberst G, Westeel V, Barnig C, Claudé F

Rev Mal Respir. 2023 06 23;:

Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report.

Hordequin L, Eberst G, Guion-Dusserre M, Gondouin A, Barnig C, Westeel V

Respir Med Res. 2023 02 20;83:101000

[A rare and atypical form of tularemia in a context of immunodepression].

Laplaza C, Barnig C, Westeel V, Eberst G

Rev Mal Respir. 2023 01 19;:

Evaluation of long-term sequelae by cardiopulmonary exercise testing 12 months after hospitalization for severe COVID-19.

Noureddine S, Roux-Claudé P, Laurent L, Ritter O, Dolla P, Karaer S, Claudé F, Eberst G, Westeel V, Barnig C

BMC Pulm Med. 2023 01 12;23(1):13

Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia.

Traore I, Eberst G, Claudé F, Laurent L, Meurisse A, Paget-Bailly S, Roux-Claudé P, Jacoulet P, Barnig C, Martarello R, Poirson B, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Pili-Floury S, Winiszewski H, Samain E, Capellier G, Westeel V

Nat Sci Sleep. 2022 12 22;14:2213-2225

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).

Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier O, Massiani MA, Langlais A, Morin F, Le Pimpec Barthes F, Brouchet L, Assouad J, Milleron B, Damotte D, Antoine M, Westeel V

J Immunother Cancer. 2022 10;10(10):

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.

Mordant P, Brosseau S, Milleron B, Santelmo N, Fraboulet-Moreau S, Besse B, Langlais A, Gossot D, Thomas PA, Pujol JL, Ricordel C, Madelaine J, Lamy R, Audigier-Valette C, Missy P, Blons H, Barlesi F, Westeel V,

Clin Lung Cancer. 2022 08 29;:

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

Westeel V, Foucher P, Scherpereel A, Domas J, Girard P, Trédaniel J, Wislez M, Dumont P, Quoix E, Raffy O, Braun D, Derollez M, Goupil F, Hermann J, Devin E, Barbieux H, Pichon E, Debieuvre D, Ozenne G, Muir JF, Dehette S, Virally J, Grivaux M, Lebargy F, Souquet PJ, Freijat FA, Girard N, Courau E, Azarian R, Farny M, Duhamel JP, Langlais A, Morin F, Milleron B, Zalcman G, Barlesi F

Lancet Oncol. 2022 08 11;:

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.

Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V

BMC Cancer. 2022 05 11;22(1):529

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clément-Duchêne C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N

Eur J Cancer. 2022 Mar 9;166:51-59

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia.

Eberst G, Claudé F, Laurent L, Meurisse A, Roux-Claudé P, Barnig C, Vernerey D, Paget-Bailly S, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Karaer S, Pili-Floury S, Winiszewski H, Samain E, Decavel P, Capellier G, Westeel V

Ann Intensive Care. 2022 Mar 9;12(1):23

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F,

Cancer Radiother. 2022 Mar 5;:

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.

Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S

ESMO Open. 2022 Feb 25;7(2):100418

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.

Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B

J Clin Oncol. 2022 Jan 24;:JCO2101455

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.

Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Thillays F, Quantin X, Oulkhouir Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game L, Besse B, Girard N

Eur J Cancer. 2021 Dec 26;162:118-127

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N

ESMO Open. 2021 Dec 22;7(1):100353

Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.

Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M

Lung Cancer. 2021 Nov 30;164:84-90

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lung Cancer. 2021 Aug 29;161:98-107

Central nervous system metastases in thymic epithelial tumors: a brief report of real-world insight from RYTHMIC.

Benitez JC, Boucher ME, Dansin E, Kerjouan M, Bigay-Game L, Pichon E, Thillays F, Falcoz PE, Lyubimova S, Oulkhouir Y, Calcagno F, Thiberville L, Clément-Duchêne C, Westeel V, Missy P, Thomas P, Maury JM, Molina T, Girard N, Besse B

J Thorac Oncol. 2021 Aug 26;:

Management of lung cancer patients' quality of life in clinical practice: a Delphi study.

Westeel V, Bourdon M, Cortot AB, Debieuvre D, Toffart AC, Acquadro M, Arnould B, Lambert J, Cotte FE, Gaudin AF, Lemasson H

ESMO Open. 2021 Aug 10;6(4):100239

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.

Anota A, Pozet A, Lemasson H, Cotté FE, Falcoz A, Eberst G, Mouillet G, Guerzider S, Charton É, Westeel V

Qual Life Res. 2021 Jul 20;:

Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.

Westeel V

J Thorac Oncol. 2021 May;16(5):719-721

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2021 Apr 30;4:CD013257

[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)].

Tougeron D, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hardy-Bessard AC, Hoang Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O, ,,,,,,,,,,,,,

Bull Cancer. 2021 Apr 12;:

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).

Tougeron D, Hentzien M, Seitz-Polski B, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hoang-Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mansi L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O, ,,,,,,,,,,,,,,,

Eur J Cancer. 2021 Apr 1;150:232-239

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Eur J Cancer. 2021 Mar 26;150:1-9

Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening.

Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel MP, Wislez M, Westeel V, Zalcman G, Scherpereel A, Khalil A

Diagn Interv Imaging. 2021 Feb 26;:

[Recommendations of French specialists on screening for lung cancer].

Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel MP, Wislez M, Westeel V, Zalcman G, Scherpereel A, Khalil A

Rev Mal Respir. 2021 Feb 23;:

RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection.

Basse C, Botticella A, Molina TJ, Falcoz PE, Oulkhouir Y, Kerjouan M, Pichon E, Westeel V, Thiberville L, Quantin X, Clément-Duchêne C, Khalifa J, Tinier FL, Ginoux M, Thillays F, Mordant P, Besse B, Thomas PA, Péchoux CL, Girard N

Clin Lung Cancer. 2021 Feb 4;:

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S

Qual Life Res. 2021 Jan 2;:

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2020 Dec 14;12:CD013257

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Lo Russo G, Signorelli D, Garassino MC, Soria JC, Caramella C, Besse B

JCO Precis Oncol. 2020 Nov;4:829-840

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

Quoix E, Audigier-Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Moreau L, Madelaine J, Dumont P, Margery J, Debieuvre D, Renault PA, Pujol JL, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ

Eur. J. Cancer. 2020 Sep 5;138:193-201

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by Mutation Subtypes.

Ruppert AM, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazières J, Bringuier PP, Monnet I, Escande F, Ricordel C, Merlio JP, Janicot H, Lemoine A, Foucher P, Poudenx M, Morin F, Langlais A, Souquet PJ, Barlesi F, Wislez M

JTO Clin Res Rep. 2020 Sep;1(3):100052

Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients.

Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D

Clin. Cancer Res.. 2020 Aug 28;:

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.

Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Floury SP, Capellier G, Lepiller Q, Orillard E, Mansi L, Clairet AL, Westeel V, Limat S, Dubois M, Malinowski L, Bohard L, Borg C, Chirouze C, Bouiller K

J. Infect.. 2020 Aug 24;:

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V

Cancer Immunol. Immunother.. 2020 Jul 16;:

Risk of scleroderma according to the type of immune checkpoint inhibitors.

Terrier B, Humbert S, Preta LH, Delage L, Razanamahery J, Laurent-Roussel S, Mestiri R, Beaudeau L, Legendre P, Goupil F, Hadjadj J, Stolzenberg MC, Treluyer JM, Westeel V, Valnet-Rabier MB, Wislez M, Mouthon L, Chouchana L

Autoimmun Rev. 2020 Jun 12;:102596

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.

Girard N, Greillier L, Zalcman G, Cadranel J, Moro-Sibilot D, Mazières J, Audigier-Valette C, Bennouna J, Besse B, Cortot A, Couraud S, Duruisseaux M, Giroux-Leprieur E, Toffart AC, Westeel V, Wislez M,

Respir Med Res. 2020 May 24;78:100769

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Leprieur EG, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG

Clin Lung Cancer. 2020 May 8;:

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.

Putora PM, Fischer GF, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman BJ, Troost EGC, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D

Radiother Oncol. 2020 Apr 20;149:84-88

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.

Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Pérol M

Oncoimmunology. 2020 Apr 12;9(1):1744898

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.

Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM

Lung Cancer. 2020 Mar 30;146:6-11

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ

Clin. Cancer Res.. 2020 Mar 6;:

Development and Validation of a Simplified Prognostic Score in SCLC.

Negre E, Coffy A, Langlais A, Daures JP, Lavole A, Quoix E, Molinier O, Greillier L, Audigier-Valette C, Moro-Sibilot D, Westeel V, Morin F, Roch B, Pujol JL

JTO Clin Res Rep. 2020 Mar;1(1):100016

Vemurafenib in non-small-cell lung cancer patients with BRAF and BRAF mutations.

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY

Ann. Oncol.. 2020 Feb;31(2):289-294

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.

Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, Pujol JL, Langlais A, Morin F, Zalcman G, Levallet G

Cancers (Basel). 2019 Nov 21;11(12):

Quality of life with durvalumab in stage III non-small-cell lung cancer.

Anota A, Westeel V

Lancet Oncol.. 2019 Oct 7;:

Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.

Leroy T, Monnet E, Guerzider S, Jacoulet P, De Bari B, Falcoz PE, Gainet-Brun M, Lahourcade J, Alfreijat F, Almotlak H, Adotevi O, Pernet D, Polio JC, Desmarets M, Woronoff AS, Westeel V

Lung Cancer. 2019 Sep 3;137:23-30

Distinct prognostic value of circulating anti-telomerase CD4 Th1 immunity and exhausted PD-1/TIM-3 T cells in lung cancer.

Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O

Br. J. Cancer. 2019 Jul 30;:

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D,

Eur. J. Cancer. 2019 Jun 7;116:86-97

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V

Clin. Cancer Res.. 2019 Jun 7;:

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D

Radiother Oncol. 2019 Apr;133:163-166

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ

Radiother Oncol. 2019 Mar 15;135:74-77

Circulating NKp46 Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O

Oncoimmunology. 2019 ;8(2):e1527498

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C

BMC Cancer. 2018 Oct 22;18(1):1013

Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial.

Quoix E, Audigier Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Dumont P, Moreau L, Madelaine J, Margery J, Debieuvre D, Renault PA, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii744-viii745

Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial.

Mazières J, Montané L, Barlesi F, Quantin X, Trédaniel J, Le Treut J, Avrillon V, Lavolé A, Westeel V, Orsini Piocelle F, Pichon E, Thiberville L, Borel C, Renault PA, Jaffro M, Collot S, Ferretti G, Legrand F, Mahier Ait Oukhatar C, Blay JY

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii538-viii539

Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial.

Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P

Eur. Respir. J.. 2018 Sep 27;:

A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.

Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, Chiari R, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D

J Thorac Oncol. 2018 Sep 11;:

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

JAMA Oncol. 2018 Sep 6;:

Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?

Quoix E, Westeel V

J Thorac Dis. 2018 Sep;10(Suppl 26):S3043-S3046

Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N

J Thorac Oncol. 2018 Aug 20;:

Cost-effectiveness of , and testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J,

Eur. Respir. J.. 2018 Mar;51(3):

Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B

ERJ Open Res. 2018 Jan;4(1):

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F

Eur. Respir. J.. 2017 Aug;50(2):

Multidisciplinary tumor board decision-making for postoperative radiotherapy in thymic epithelial tumors: Insights from the RYTHMIC prospective cohort.

Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clement-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N

J Thorac Oncol. 2017 Jul;:

Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib.

Jacquin-Porretaz C, Nardin C, Blanc D, Aubin F, Gérard B, Drobacheff-Thiebaut C, Jacoulet P, Westeel V

J Thorac Oncol. 2017 May;12(5):e47-e48

Surrogate endpoints for overall survival in lung cancer trials: a review.

Fiteni F, Westeel V, Bonnetain F

Expert Rev Anticancer Ther. 2017 May;17(5):447-454

Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.

Fiteni F, Paillard MJ, Westeel V, Bonnetain F

Expert Rev Anticancer Ther. 2017 Feb;17(2):167-173

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G

Oncotarget. 2017 Jan;8(3):4313-4329

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ

PLoS ONE. 2017 ;12(8):e0182798

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V

Eur. Respir. J.. 2016 Sep;48(3):861-72

High-resolution CT predictors of hypersensitivity pneumonitis.

Rival G, Manzoni P, Lacasse Y, Polio JC, Westeel V, Dubiez A, Soumagne T, Laurent F, Dalphin JC

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Aug;33(2):117-23

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O

Oncoimmunology. 2016 May;5(5):e1137416

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G,

Lancet. 2016 Apr;387(10026):1415-26

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O

Ann. Oncol.. 2016 Feb;27(2):281-6

Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review.

Fiteni F, Anota A, Westeel V, Bonnetain F

BMC Cancer. 2016 Feb;16:122

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM

Lancet Oncol.. 2016 Feb;17(2):212-23

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V

Eur. J. Cancer. 2016 Jan;52:120-8

[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer].

Milleron B, Westeel V, Gounant V, Wislez M, Quoix E

Bull Cancer. 2016 Jan;103(1):66-72

Access to Innovative Drugs in Patients with Metastatic Lung Cancer in French Public Hospitals (the Territoire Study).

Scherpereel A, Fernandes J, Cotte F, Blein C, Debieuvre D, Durand-Zaleski I, Gaudin A, Ozan N, Saitta B, Souquet P, Vainchtock A, Westeel V, Chouaid C

Value Health. 2015 Nov;18(7):A341

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.

Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G

Eur Respir J. 2015 Sep 17. pii: ERJ-02358-2014

Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.

Fiteni F, Pam A, Anota A, Vernerey D, Paget-Bailly S, Westeel V, Bonnetain F

Expert Rev Anticancer Ther. 2015 May 31:1-7.

2nd ESMO Consensus Conference in Lung Cancer: locally-advanced stage III non-small-cell lung cancer (NSCLC).

Eberhardt WE, De Ruysscher D, Weder W, Le Pechoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S

Ann Oncol. 2015 Apr 20. pii: mdv187.

[Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].

Fiteni F, Anota A, Westeel V, Bonnetain F

Bull Cancer. 2015 Apr;102(4):360-6

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morere JF

J Geriatr Oncol. 2015 Feb 16. pii: S1879-4068(15)00009-0

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F

Qual Life Res. 2015 Jan;24(1):5-18

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C,

BMC Cancer. 2014 Dec;14:953

Endpoints in cancer clinical trials.

Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F

J Visc Surg. 2014 Feb;151(1):17-22

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G

Eur Respir J. 2014 Jan;43(1):240-9

[What if living on a farm protected against lung cancer, too?].

Dalphin JC, Paulus V, Westeel V

Rev Mal Respir. 2013 Dec;30(10):809-11

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Riviere A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarie E, Morin F, Depierre A, Milleron B

Eur J Cancer. 2013 Aug;49(12):2654-64

Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.

Bylicki O, Ferlay C, Chouaid C, Lavole A, Barlesi F, Dubos C, Westeel V, Crequit J, Corre R, Vergnenegre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Perol D, Zalcman G, Perol M

J Thorac Oncol. 2013 Jul;8(7):906-14

Chemotherapy versus best supportive care for extensive small cell lung cancer.

Pelayo Alvarez M, Westeel V, Cortes-Jofre M, Bonfill Cosp X

Cochrane Database Syst Rev. 2013 Nov 27;11:CD001990

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP

J Thorac Oncol. 2012 Oct;7(10):1490-502.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V, Crequit J, Lena H, Vergnenegre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Segura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B

J Clin Oncol. 2012 Oct 1;30(28):3516-24

Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.

Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coetmeur D, Monnet I, Mourlanette P, Morere JF, Soria JC, Westeel V, Morin F, Cadranel J

J Thorac Oncol. 2012 Sep;7(9):1423-31.

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G

Clin Cancer Res. 2012 May 15;18(10):2976-86

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G

Mol Cancer Ther. 2012 May;11(5):1203-13

Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.

Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V,

J Thorac Oncol. 2012 May;7(5):841-9

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C

Eur Respir J. 2012 Jan;39(1):172-9

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations.

Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts S, Lafitte JJ, Lecomte J, Louviaux I, Markiewicz E, Meert AP, Richez M, Roelandts M, Scherpereel A, Tulippe Ch, Van Houtte P, Van Schil P, Wachters C, Westeel V, Sculier JP

Eur Respir J. 2012 Jan;39(1):9-28

Chemotherapy in elderly patients with advanced non-small cell lung cancer.

Quoix E, Westeel V, Zalcman G, Milleron B

Lung Cancer. 2011 Dec;74(3):364-8

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM

Lancet Oncol. 2011 Nov;12(12):1125-33

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducolone A, Lebitasy MP, Baudrin L, Laporte S, Milleron B

Lancet. 2011 Sep 17;378(9796):1079-88

[Non-small cell lung cancer: Perioperative treatments].

Westeel V, Schipman B, Jacoulet P

Presse Med. 2011 Apr;40(4 Pt 1):398-403

[Bevacizumab and lung cancer: eligible patients in daily practice].

Lagnien-Gaume V, Jehl J, Manzoni P, Jacoulet P, Gainet-Brun M, Metzger F, Pernet D, Polio JC, Pugin JF, Corgne J, Amoros C, Dalphin JC, Westeel V

Rev Mal Respir. 2011 Jan;28(1):25-31

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).

Morere JF, Brechot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlesi F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D

Lung Cancer. 2010 Dec;70(3):301-7

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors.

Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, Westeel V, Villanueva C, Woronoff-Lemsi MC, Pivot X

Int J Med Inform. 2010 Oct;79(10):699-706.

Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice

Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A, Dalphin JC, Westeel V

J Thorac Oncol. 2009 Dec;4(12):1544-9.

What's new in early stages?

Westeel V

Rev Pneumol Clin. 2009 Dec;65 Suppl. 2:S61-5

Treatment of nonirradiable stage IIIB-IV CBNPC: towards and individualized treatment? Should classic criteria (age, sex...) influence our practices in 2008?

Westeel V

Rev Pneumol Clin. 2008 Nov;64:27-9

Oncological management of the operated patient: adjuvant chemotherapy, surveillance, treatment of recurrences

Westeel V, Moro-Sibilot D

Oncologie. 2008 Sep;10(9):525-8

Rurality and survival differences in lung cancer: a large population-based multivariate analysis.

Pozet A, Westeel V, Berion P, Danzon A, Debieuvre D, Breton JL, Monnier A, Lahourcade J, Dalphin JC, Mercier M

Lung Cancer. 2008 Mar;59(3):291-300

Practice of perioperative chemotherapy for non small cell lung cancer

Westeel V

Rev Mal Respir. 2007 Oct;24(8):S69-72

[Practice of perioperative chemotherapy for non small cell lung cancer]

Westeel V

Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S69-72.

[Preoperative chemotherapy in non-small cell lung cancer: advantages, disadvantages, level of evidence]

Depierre A, Westeel V

Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S59-63.

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D

J. Clin. Oncol.. 2007 Sep;25(25):3945-51

Twelve-year longitudinal study of respiratory status in dairy farmers.

Gainet M, Thaon I, Westeel V, Chaudemanche H, Venier AG, Dubiez A, Laplante JJ, Dalphin JC

Eur Respir J. 2007 Jul;30(1):97-103

[Treatment of localised lung cancer]

Depierre A, Westeel V

Pathol Biol (Paris). 2007 Jul;55(6):299-303

Lung cancer in the elderly subject

Albrand G, Biron E, Boucot I, Couderc LJ, Crestani B, Dombret MC, Guenard H, Grivaux M, Hervy MP, Housset B, Jougon J, Orvoen-Frija E, Piette F, Pignon T, Pinganaud G, Puisieux F, Quoix E, Sauty E, Vaylet F, Wary B, Weill-Engerer S, Westeel V, Wislez M

Rev Mal Respir. 2007 Jun;24(6):703-23.

[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

Westeel V, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A,

Rev Mal Respir. 2007 May;24(5):645-52

Follow up of non small cell lung cancer - Should patients be followed up after surgery for nonsmall cell lung cancer and how?.

Westeel V

. 2006 Nov;23(5 Pt 3):S84-7.

[Follow up of non small cell lung cancer. Should patients be followed up after surgery for non-small cell lung cancer and how?].

Westeel V

Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S84-16S87.

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

Westeel V, Breton JL, Braun D, Quoix E, Milleron B, Debieuvre D, Jacoulet P, Germa C, Kayitalire L, Depierre A

Lung Cancer. 2006 Mar;51(3):347-55

[Can therapeutic strategy favor the passage to chronicity in metastatic non-small-cell lung cancer?].

Westeel V

Rev Pneumol Clin. 2006 Feb;62 Spec no 1:1S14-5.

Postoperative follow-up in non-small cell lung cancer.

Westeel V

Rev Mal Respir. 2005 Dec;22(6 Pt 2):S90-3.

[Postoperative follow-up in non-small cell lung cancer].

Westeel V

Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S90-3.

Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database.

Milleron B, Westeel V, Quoix E, Moro-Sibilot D, Braun D, Lebeau B, Depierre A

Chest. 2005 Sep;128(3):1442-7.

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.

Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard P, Haller MA, Milleron B, Herman D, Level MC, Lebas FX, Puyraveau M, Depierre A

J Natl Cancer Inst. 2005 Apr 6;97(7):499-506.

Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000).

Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Bréchot JM, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Lemarié E, Martinet Y, Massard G, Milleron B, Molina T, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix E, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet PJ, Spaeth D, Stoebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon JM, Westeel V,

Br. J. Cancer. 2003 Aug;89 Suppl 1:S35-49

[Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients].

Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Bréchot JM, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Lemarié E, Martinet Y, Massard G, Milleron B, Molina T, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix E, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet JP, Spaeth D, Stoebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon JM, Westeel V

Bull Cancer. 2003 Feb;90(2):151-66

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C

J Clin Oncol. 2002 Jan 1;20(1):247-53.